Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients
Chin-Chou Huang,1–5 Min-Ji Charng2,3 1Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan; 2Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; 3Faculty of Medicine, School of Medicine, National Yang–Ming...
Main Authors: | Huang CC, Charng MJ |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-10-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/clinical-evaluation-of-evolocumab-for-the-treatment-of-homozygous-fami-peer-reviewed-article-TCRM |
Similar Items
-
Efficacy of Evolocumab in Patients with Hypercholesterolemia
by: Xuan Jin, et al.
Published: (2020-12-01) -
Phenotypic homozygous familial hypercholesterolemia successfully treated with proprotein convertase subtilisin/kexin type 9 inhibitors
by: Ryosuke Tani, et al.
Published: (2024-02-01) -
Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
by: Olga Afanasieva, et al.
Published: (2020-10-01) -
Effectiveness and safety of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with familial hypercholesterolemia. Our experience in implementing the drug program of the Polish National Health Fund
by: Beata Bobrowska, et al.
Published: (2022-08-01) -
Familial Hypercholesterolemia
by: FENG Siqin, et al.
Published: (2023-01-01)